WJ Valentine

Author response for "Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the US "

WJ Valentine, M Hoog, R Mody, M Belger et autres

EE137 Evaluating the Effects of the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model Risk Factor Progression Equations on Cost-Utility Outcomes in Type 2 Diabetes: Analyses Using the Prime Diabetes Model

Richard F. Pollock, WJ Valentine

gb (code pays fourni par la source)

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA

L. Billings, Michelle Mocarski, A Basse, Barnaby Hunt et autres

BACKGROUND: Compared with basal-bolus insulin therapy (insulin glargine U100 plus insulin aspart), IDegLira has been shown to be associated with similar improvements in HbA1c, with superior weight loss and reduced hypoglycemia in patients with type 2 diabetes. The present analysis evaluated the …

us, dk, ie, es (code pays fourni par la source)

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA

Billings LK, Michelle Mocarski, A Basse, Barnaby Hunt et autres

LK Billings,1,2 M Mocarski,3 A Basse,4 B Hunt,5 WJ Valentine,5 E Jodar6 1Division of Endocrinology and Metabolism, NorthShore University HealthSystem, Skokie, IL, USA; 2Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA; 3Value Evidence and Outcomes, Novo Nordisk …

Nasal Glucagon Saves Professional Emergency Medical (EM) Costs Versus Intramuscular Glucagon —A Us Based Cost-Offset Model

Shailendra Bajpai, John Poehlmann, Beatrice Osumili, Beth Mitchell et autres

us (code pays fourni par la source)

Evaluating the Long-Term Impact of Improving Care for Patients with Type 2 Diabetes in China

LM Wang, Qiuyu Ye, Ole Kjerkegaard Nielsen, Anne Gadegaard et autres

cn, dk (code pays fourni par la source)

Quantifying the Trade-off Between Improved Glycemic Control and Severe Hypoglycemia Risk in Patients with Type 1 Diabetes: A Health Economic Analysis in the Uk

Richard F. Pollock, WJ Valentine

Cost-Effectiveness Analysis of Liraglutide 1.8Mg Versus Lixisenatide 20μg for Patients with Type 2 Diabetes Mellitus in Italy

Nana Kragh, E Ye, WJ Valentine, Barnaby Hunt

dk (code pays fourni par la source)

Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for the Treatment of Type 2 Diabetes Mellitus in the Spanish Setting

Nana Kragh, E Ye, Barnaby Hunt, WJ Valentine

dk (code pays fourni par la source)

Projected Long-Term Outcomes in Patients with Type 1 Diabetes Mellitus Treated with Faster-Acting Insulin Aspart Versus Conventional Insulin Aspart in the UK Setting

David Russell‐Jones, Sarah Buchs, MM Jensen, Barnaby Hunt et autres

gb, dk (code pays fourni par la source)

Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for Patients with Type 2 Diabetes Mellitus in the UK Setting

Nana Kragh, E Ye, Barnaby Hunt, WJ Valentine

dk (code pays fourni par la source)

Systematic Literature Review of Health State Utilities for Adults With Type 1 Diabetes

Jayne Smith‐Palmer, KS Boye, Jay Bae, Kirsi Norrbacka et autres

us (code pays fourni par la source)